Transparent leadership

At Photocure, we believe that a strong culture begins with its leadership. That is how we create a cohesive network of colleagues, working closely together towards the same goals. We believe in exercising the highest levels of accountability, integrity and transparency in order to succeed in our common goal of achieving the best healthcare for every patient with bladder cancer.
All members of Photocure’s Board of Directors are independent directors. For committee roles and biography details, please see below.

Board of Directors

Johanna Holldack, M.D., Director

Dr. Holldack has international operational experience from pharma companies, including clinical trials, drug approvals, IPOs and licensing. She has also managed several mergers and acquisitions. In addition, Dr. Holldack has venture capital experience from Swiss-based Aravis Venture where she was a partner for 5 years. Her industry career spans over 20 years, during which she held key positions in both start-up and large pharma companies. Her experience includes management and executive positions at Behringwerke, Chiron, MediGene, Borean Pharma, Telormedix and Trethera Corporation. She is chairperson of Amal Therapeutics. Dr. Holldack has a medical degree from Georg-August-University in Göttingen, Germany and is a board certified pediatrician. In addition, she has held positions as an assistant professor at the University of Essen, research fellow for the Deutsche Krebshilfe and a research associate at Harvard Medical School. 
Johanna Holldack holds no shares in Photocure. She is is an independent director, without material relationship with Photocure and being neither part of its executive team nor involved in the company’s day-to-day operations. She is Member of the Compensation Committee and Member of the Scientific Committee.

Read more
Neal Shore, M.D., Director

Dr. Shore is Medical Director for the Carolina Urologic Research Center and is a Fellow of the American College of Surgeons. He has conducted more than 400 clinical trials focusing mainly on genitourinary oncology. Dr. Shore performs peer reviews for Lancet Oncology, New England Journal of Medicine, European Urology, the Journal of Urology, Urology, BJUI, PCPD, and other high-impact scientific journals. He serves on the executive boards of the Society of Urologic Oncology, the Bladder Cancer Advocacy Network (BCAN), and as the National Urology Research Director for GenesisCare. From 2016 to 2018 Dr. Shore was the President of the Large Urology Group Practice Association. In addition, he has served on  numerous Committees, Editorial and Review boards, such as the AUA Research and Innovations Committees, Health and Data Committees, the SITC Task Force for Prostate Cancer and Bladder Cancer, the Editorial Boards of Review in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, and the World Journal of Urology. Neal Shore holds no shares in Photocure.
He is an independent director, without material relationship with Photocure and being neither part of its executive team nor involved in the company’s day-to-day operations. He is Chairperson of the Scientific Committee & Advisor for ESG matters.

Read more

Management

Dan Schneider, President and Chief Executive Officer

Dan Schneider joined Photocure November 2018. He brings more than 25 years of experience in developing and expanding rapidly growing healthcare companies in the U.S., most recently as the General Manager for Ablynx N.V. in North America. He has also held executive management positions in other pharmaceutical and biotech companies, including BTG International, Somaxon Pharmaceuticals and Sepracor. Mr. Schneider is a U.S. citizen and holds an MBA from Washington University and a Bachelor of Science degree in Business Administration from St. Louis University with a double major in Finance and Marketing. Dan Schneider holds 332,500 share options and 99,689 shares in the Company.

Read more
Erik Dahl, Chief Financial Officer

Erik Dahl, joined Photocure in August 2012 as CFO. He has more than 30 years of experience from senior level financial management roles, with responsibilities within corporate finance, legal and financial restructurings, M&A and capital market transactions. He has held various CFO roles in both public and private companies. Mr. Dahl has a Bachelor degree in finance and accounting from the Norwegian School of Economics. Erik Dahl holds 213,750 share options and 32,750 shares in the Company.

Read more
Geoffrey Coy, Vice President & General Manager North America

Geoff Coy joined Photocure in October 2019. He has nearly 25 years of experience in the life sciences industry including sales, marketing, sales operations and market access in the biopharmaceuticals and medical device areas. Prior to joining Photocure Geoff was the Commercial Vice President of Sales and Marketing for BTG International (Boston Scientific) where he lead strategic and operational business development. Prior to BTG Geoff has been in leadership roles for Sepracor Pharmaceuticals and GlaxoSmithKline. Geoff has a proven track record and ability to build and develop high-performing commercial teams that deliver results. Geoffrey Coy holds 216,250 share options and 15,207 shares in the Company.

Read more
Anders Neijber, M.D., Chief Medical Officer, Global Medical Affairs and Clinical Development and R&D

Anders Neijber joined Photocure in August 2021, bringing over 25 years of substantial experience in the uro-oncology area and successful leadership in the pharmaceutical industry. He has had global and regional assignments, both in the U.S. and Europe, within Clinical R&D and Medical Affairs, having worked for Pfizer, AstraZeneca, Johnson & Johnson, Allergan and Ferring, where he held a similar global Medical Affairs leadership role as V.P., Global Therapeutic Area Head Uro-Oncology. Most recently he worked in Medical Affairs for Novartis in the Nordics. Anders completed his MD and PhD from Karolinska University, is a board certified urologist, and also holds an MBA. He held an assistant Professor position at the Department of Clinical Pharmacology, Robert Wood Johnson Medical School, New Jersey. Anders Neijber holds 114,000 share options in Photocure.

Read more
Susanne Strauss, Ph.D., Vice President & General Manager Europe

Susanne Strauss joined Photocure in July 2020 following Photocure's regaining worldwide rights to Hexvix® and the establishment of its own commercial operations in Europe. She brings over 20 years of international leadership experience in medical devices, life sciences and pharma, living and working across Europe and Asia with occasional remits in the U.S. Most recently Ms. Strauss held the position of General Manager of Asia Pacific for legacy BTG at Boston Scientific after leading BTG's Interventional Pulmonology Business as VP Commercial and expanding BTG's Interventional Oncology Business into Europe. Before that she worked in leadership positions for Convatec, Janssen-Cilag and Baxter. She holds a PhD in Technical Chemistry and an MBA from SDA Bocconi. Susanne Strauss holds 203,750 share options and 1392 shares in the Company.

Read more

Nomination Committee

Photocure has a Nomination Committee making recommendations to the general meeting regarding election of shareholder-elected members of the Board of Directors, remuneration to the members of the Board of Directors, election of members to the Nomination Committee and remuneration to the members of the Nomination Committee.

Please see the latest report of the Nomination Committee here.

News and Events